PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Pembrolizumab
DRUG: Infliximab
DRUG: Placebo
DRUG: Relatlimab
DRUG: Nivolumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]